.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Express Scripts
QuintilesIMS
Accenture
Dow
Medtronic
Johnson and Johnson
Citi
Covington
Baxter

Generated: June 26, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,785,627

« Back to Dashboard

Which drugs does patent 7,785,627 protect, and when does it expire?


Patent 7,785,627 protects ACTOPLUS MET XR and is included in one NDA. There has been one Paragraph IV challenge on Actoplus Met XR.

This patent has seventy-one patent family members in twenty-four countries.

Summary for Patent: 7,785,627

Title:Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
Abstract:A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.
Inventor(s): Kositprapa; Unchalee (Davie, FL), Goldfarb; Robert I. (Golden Beach, FL), Cardinal; John (Tamarac, FL), Nangia; Avinash (Weston, FL)
Assignee: Watson Pharmaceuticals, Inc. (Corona, CA)
Application Number:10/664,803
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Takeda Pharms Usa
ACTOPLUS MET XR
metformin hydrochloride; pioglitazone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022024-001May 12, 2009RXYesNo7,785,627► SubscribeY
Takeda Pharms Usa
ACTOPLUS MET XR
metformin hydrochloride; pioglitazone hydrochloride
TABLET, EXTENDED RELEASE;ORAL022024-002May 12, 2009RXYesYes7,785,627► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,785,627

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,470,368Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative► Subscribe
9,060,941Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative► Subscribe
7,959,946Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative► Subscribe
8,309,125Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative► Subscribe
8,668,931Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,785,627

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea101249171► Subscribe
South Korea20110126761► Subscribe
Japan2013209426► Subscribe
Japan6054909► Subscribe
Japan2014196314► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
QuintilesIMS
Teva
Colorcon
Healthtrust
Harvard Business School
Covington
Novartis
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot